Drugs / F373280
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01831856 | Apr 2013 → Apr 2017 | atrial fibrillation | Pierre Fabre Laboratories | Completed | Missed primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | F373280 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01831856 ↗ |
| Route | Oral | “Oral administration, one capsule each evening with dinner.” NCT01831856 ↗ |